{
    "nct_id": "NCT04885998",
    "official_title": "A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in Combination With AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)",
    "inclusion_criteria": "* Participant has provided informed consent/assent prior to initiation of any study specific activities/procedures\n* Age greater than or equal to 18 years old at the same time of signing the informed consent\n* Participants with histologically or cytologically confirmed Small Cell Lung Cancer (SCLC) who progressed or recurred following at least 1 platinum-based regimen\n* Eastern Cooperative Oncology Group (ECOG) 0 to 1\n* Participants with treated brain metastases are eligible provided they meet defined criteria\n* Adequate organ function as defined in protocol\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of other malignancy within the past 2 years with exceptions\n* Major surgery within 28 days of first dose of tarlatamab\n* Untreated or symptomatic brain metastases and leptomeningeal disease\n* Prior anti-cancer therapy, including anti-PD1 or anti-PDL1 antibody therapy: at least 28 days must have elapsed between any prior anti-cancer therapy and the first planned dose of tarlatamab\n\nExceptions:\n\n* Participants who received prior chemotherapy must have completed at least 14 days before the first dose of tarlatamab and all treatment-related toxicity resolved to grade â‰¤ 1.\n* Participants who received prior palliative radiotherapy must have completed at least 7 days before the first dose of tarlatamab\n\n  * Participants who received prior tarlatamab therapy or prior delta-like ligand 3 (DLL3) x cluster of differentiation 3 (CD3) bispecific therapy are not eligible\n  * Participants who experienced recurrent grade 2 pneumonitis or severe or life-threatening immune-mediated adverse events or infusion-related reactions including those that lead to permanent discontinuation while on treatment with immuno-oncology agents\n  * History of any immune-related colitis. Infectious colitis is allowed if evidence of adequate treatment and clinical recovery exists and at least 3 months interval observed since diagnosis of colitis\n  * Participants with evidence of interstitial lung disease or active, non-infectious pneumonitis\n  * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of tarlatamab\n  * History of solid organ transplantation\n  * History of hypophysitis or pituitary dysfunction\n  * Active autoimmune disease that has required systemic treatment (except replacement therapy) within the past 2 years or any other diseases requiring immunosuppressive therapy while on study. Participants with Type I diabetes, vitiligo, psoriasis, hypo- or hyper-thyroid disease not requiring immunosuppressive treatment are permitted",
    "miscellaneous_criteria": ""
}